PMID: 9536923Apr 16, 1998Paper

An early prenatal exposure to excess glucocorticoid leads to hypertensive offspring in sheep

Clinical Science
M DodicJ P Coghlan

Abstract

1. Recent studies in animals have linked fetal exposure to excess maternal glucocorticoids with the later occurrence of cardiovascular disorders, particularly hypertension. 2. To test the hypothesis that prenatal treatment could impact on adult blood pressure two groups of pregnant ewes were transported from the farm to the Institute at either 22-29 days of pregnancy (pretreatment group 1) or 59-66 days of pregnancy (pretreatment group 2), subjected to 48 h treatment with dexamethasone (0.28 mg day-1 kg-1 for 2 days) and then returned to the farm. The control group remained at the farm for the entire pregnancy. Lambs were then studied at approximately 4, 10 and 19 months after birth. 3. The basal mean arterial pressure in pretreatment group 1 (80 +/- 1 mmHg at 124 days; 83 +/- 1 mmHg at 309 days and 89 +/- 1 mmHg at 558 days; n = 6) was significantly different (P < 0.05 in all groups) from that in the control group of lambs (74 +/- 2 mmHg at 110 days; 76 +/- 1 mmHg at 323 days and 81 +/- 1 mmHg at 568 days; n = 7). However, prenatal glucocorticoid exposure did not alter vascular sensitivity to noradrenaline, angiotensin II and adrenocorticotropic hormone in these sheep at any of the ages studied, nor did it affect basal or adre...Continue Reading

Citations

Feb 19, 2002·Kidney International·Vicky HantzisMiodrag Dodic
Feb 13, 2001·Kidney International·A PeersE M Wintour
Sep 18, 2012·Best Practice & Research. Clinical Endocrinology & Metabolism·Batbayar Khulan, Amanda J Drake
Feb 26, 2010·Early Human Development·Patricia Helen Carvalho RondóJosé Maria Pacheco Souza
May 28, 2008·Gender Medicine·Daniela GrigoreBarbara T Alexander
Feb 6, 2008·Seminars in Perinatology·Lex W Doyle
Jan 29, 2005·Annals of the New York Academy of Sciences·Jonathan R Seckl, Michael J Meaney
May 29, 2009·Clinical and Experimental Pharmacology & Physiology·Karen M MoritzRoger G Evans
Aug 2, 2008·Clinical and Experimental Pharmacology & Physiology·Robert De MatteoRichard Harding
Feb 26, 2009·British Journal of Pharmacology·Patrick W F HadokeBrian R Walker
Feb 21, 2006·Clinical and Experimental Pharmacology & Physiology·Maria A MatuszekGiuseppe Simonetta
Aug 8, 2006·Annals of the New York Academy of Sciences·Jonathan R Seckl, Michael J Meaney
Sep 14, 2012·Clinical and Experimental Pharmacology & Physiology·Reetu R SinghKaren M Moritz
Nov 26, 2009·Clinical and Experimental Pharmacology & Physiology·Helena C ParkingtonMarianne Tare
Jan 27, 2005·American Journal of Obstetrics and Gynecology·Timothy J M MossJohn P Newnham
Sep 3, 2005·Early Human Development·Samantha Louey, Kent L Thornburg
May 17, 2006·Trends in Ecology & Evolution·Peter D GluckmanHamish G Spencer
Dec 15, 2010·Frontiers in Neuroendocrinology·Caitlin S WyrwollJonathan R Seckl
Apr 30, 2002·Placenta·Keith M Godfrey
Nov 25, 2003·American Journal of Obstetrics and Gynecology·Heiner ZimmermannAlison J Forhead
Mar 12, 2013·Journal of Pregnancy·Bonnie BrensekeJ Claudio Gutierrez
Mar 17, 2001·Clinical and Experimental Pharmacology & Physiology·A PeersM Dodic
Nov 13, 2001·Clinical and Experimental Pharmacology & Physiology·E R LumbersK J Gibson
Nov 13, 2001·Clinical and Experimental Pharmacology & Physiology·M DodicE M Wintour

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.